Hakutulokset - Castellano, Daniel

Tarkenna hakua
  1. 1
    Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature

    Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature Tekijä de Velasco, Guillermo, Munoz, Cesar, Sepulveda, Juan M., Castellano, Daniel

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  2. 2
    Three case reports: Temporal association between tyrosine-kinase inhibitor-induced hepatitis and immune checkpoint inhibitors in renal cell carcinoma

    Three case reports: Temporal association between tyrosine-kinase inhibitor-induced hepatitis and immune checkpoint inhibitors in renal cell carcinoma Tekijä Carretero-González, Alberto, Salamanca Santamaría, Javier, Castellano, Daniel, de Velasco, Guillermo

    Julkaistu 2019
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  3. 3
    Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.

    Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis. Tekijä Carretero-González, Alberto, Otero, Irene, Lora, David, Carril-Ajuria, Lucía, Castellano, Daniel, de Velasco, Guillermo

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  4. 4
    The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab

    The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab Tekijä Castellano, Daniel, Sepulveda, Juan Manuel, García-Escobar, Ignacio, Rodriguez-Antolín, Alfredo, Sundlöv, Anna, Cortes-Funes, Hernán

    Julkaistu 2011
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  5. 5
    Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials

    Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials Tekijä Carretero-González, Alberto, Lora, David, Ghanem, Ismael, Otero, Irene, López, Flora, Castellano, Daniel, de Velasco, Guillermo

    Julkaistu 2019
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  6. 6
    Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials

    Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomiz... Tekijä Manneh, Ray, Lema, Mauricio, Carril-Ajuria, Lucía, Ibatá, Linda, Martínez, Susan, Castellano, Daniel, de Velasco, Guillermo

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  7. 7
    Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study

    Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study Tekijä Castellano, Daniel, Bajetta, Emilio, Panneerselvam, Ashok, Saletan, Stephen, Kocha, Walter, O'Dorisio, Thomas, Anthony, Lowell B., Hobday, Timothy

    Julkaistu 2013
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  8. 8
    Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning

    Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning Tekijä Durán, Ignacio, Castellano, Daniel, Puente, Javier, Martín-Couce, Lidia, Bello, Esther, Anido, Urbano, Mas, José Manuel, Costa, Luis

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  9. 9
    Cabozantinib for the treatment of solid tumors: a systematic review

    Cabozantinib for the treatment of solid tumors: a systematic review Tekijä Maroto, Pablo, Porta, Camillo, Capdevila, Jaume, Apolo, Andrea B., Viteri, Santiago, Rodriguez-Antona, Cristina, Martin, Lidia, Castellano, Daniel

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  10. 10
    Cabozantinib combination therapy for the treatment of solid tumors: a systematic review

    Cabozantinib combination therapy for the treatment of solid tumors: a systematic review Tekijä Castellano, Daniel, Apolo, Andrea B., Porta, Camillo, Capdevila, Jaume, Viteri, Santiago, Rodriguez-Antona, Cristina, Martin, Lidia, Maroto, Pablo

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  11. 11
    Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature

    Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature Tekijä Guillem, Vicente, Climent, Miguel Angel, Cassinello, Javier, Esteban, Emilio, Castellano, Daniel, González-Larriba, José Luis, Maroto, Pablo, Camps, Carlos

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  12. 12
    Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case

    Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case Tekijä Manneh, Ray, Castellano, Daniel, Caso, Oscar, Loinaz, Carmelo, Jiménez, Jesús, Estenoz, Juana, Calatayud, Maria, Sepúlveda, Juan M., García-Carbonero, Rocio

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  13. 13
    Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate

    Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY215729... Tekijä SEPULVEDA-SANCHEZ, JUAN, RAMOS, ANA, HILARIO, AMAYA, DE VELASCO, GUILLERMO, CASTELLANO, DANIEL, GARCIA DE LA TORRE, MARTA, RODON, JORDI, LAHN, MICHAEL F.

    Julkaistu 2015
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  14. 14
    Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice

    Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clini... Tekijä Castellano, Daniel, Puente, Javier, de Velasco, Guillermo, Chirivella, Isabel, López-Criado, Pilar, Mohedano, Nicolás, Fernández, Ovidio, García-Carbonero, Icíar, González, María Belén, Grande, Enrique

    Julkaistu 2014
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  15. 15
    Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials

    Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials Tekijä Carretero-González, Alberto, Lora, David, Ghanem, Ismael, Zugazagoitia, Jon, Castellano, Daniel, Sepúlveda, Juan M., López-Martin, José A., Paz-Ares, Luis, de Velasco, Guillermo

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  16. 16
    The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials

    The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials Tekijä Carretero-González, Alberto, Lora, David, Martín Sobrino, Isabel, Sáez Sanz, Irene, Bourlon, María T., Anido Herranz, Urbano, Martínez Chanzá, Nieves, Castellano, Daniel, de Velasco, Guillermo

    Julkaistu 2020
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  17. 17
    Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis

    Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis Tekijä Carretero-González, Alberto, Hergueta-Redondo, Marta, Sánchez-Redondo, Sara, Ximénez-Embún, Pilar, Manso Sánchez, Luis, Gil, Eva Ciruelos, Castellano, Daniel, de Velasco, Guillermo, Peinado, Héctor

    Julkaistu 2022
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  18. 18
    Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients

    Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients Tekijä Liu, Xiaoyan, Swen, Jesse J., Boven, Epie, Castellano, Daniel, Gelderblom, Hans, Mathijssen, Ron H.J., Rodríguez-Antona, Cristina, García-Donas, Jesus, Rini, Brian I., Guchelaar, Henk-Jan

    Julkaistu 2016
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  19. 19
    Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease

    Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-... Tekijä Suzuki, Hiroyoshi, Castellano, Daniel, de Bono, Johann, Sternberg, Cora N, Fizazi, Karim, Tombal, Bertrand, Wülfing, Christian, Foster, Meredith C, Ozatilgan, Ayse, Geffriaud-Ricouard, Christine, de Wit, Ronald

    Julkaistu 2021
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:
  20. 20
    Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study

    Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study Tekijä Capdevila, Jaume, Teulé, Alexandre, Barriuso, Jorge, Castellano, Daniel, Lopez, Carlos, Manzano, Jose Luis, Alonso, Vicente, García‐Carbonero, Rocío, Dotor, Emma, Matos, Ignacio, Custodio, Ana, Casanovas, Oriol, Salazar, Ramon

    Julkaistu 2018
    Hae kokoteksti Hae kokoteksti Hae kokoteksti
    Teksti
    Lisää suosikkeihin
    Tallennettuna:

Työkalut: